Deepeye Medical provides an AI‑powered digital second‑opinion platform that analyzes OCT scans to detect retinal biomarkers and predict therapy needs for up to 12 months. The device‑agnostic solution integrates via plug‑ins with existing imaging software, delivering expert‑calibrated reports that help retina specialists personalize treatment intervals and improve visual outcomes.
Funding
$2.7M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
2OFounders
Product
Problem
Ophthalmologists often rely on a single expert reading of OCT scans, which can miss subtle disease activity and lead to suboptimal treatment decisions, especially in busy clinics lacking longitudinal data and standardized AI tools.
Solution
Deepeye Medical offers an AI-powered digital second opinion platform that analyzes OCT images to identify retinal biomarkers and forecast therapy needs for the next 12 months. The system is device‑agnostic, supporting images from major OCT manufacturers, and draws on a curated dataset of nearly one million scans annotated by certified retina specialists. By providing therapy quality‑assurance, optimal prognosis, and biomarker quantification, the platform helps clinicians personalize treatment intervals and improve visual outcomes. Integration is achieved through simple plug‑ins to existing imaging software, enabling rapid deployment without workflow disruption. The AI outputs are validated against expert ground truth and presented as actionable recommendations within the clinician’s existing interface.
Target Audience
Primary users are retina specialists and ophthalmology clinics seeking AI‑assisted diagnostic support, as well as pharmaceutical companies conducting retinal therapy research.
Features
- Device‑agnostic OCT processing compatible with >95% of scanners (Heidelberg Spectralis, Zeiss Cirrus, Topcon Triton, etc.)
- Automated biomarker detection and quantification across multiple retinal diseases
- Predictive therapy planning that estimates treatment needs for up to 12 months based on longitudinal OCT data
- Digital second‑opinion reports calibrated to expert ground‑truth annotations, enhancing diagnostic confidence
- Seamless integration via plug‑ins to standard OCT imaging software with minimal setup time
- Access to a large, diverse training dataset (≈1 million scans) ensuring robust performance across populations